Collplant advances its 3d bioprinted regenerative breast implants into porcine study

Rhcollagen-based regenerative breast implants address $2.8 billion global breast implant market with revolutionary and potentially safer new product regenerative breast implants for aesthetic and reconstructive procedures including postmastectomy for cancer patients the study is planned to be concluded within six months rehovot, israel , june 28, 2022 /prnewswire/ -- collplant (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced the initiation of a study in large animals for its 3d bioprinted regenerative breast implant program, addressing the $2.8 billion global breast implant market. "this study is a quantum leap in the development of 3d bioprinted regenerative breast implants," said yehiel tal, collplant's chief executive officer.
CLGN Ratings Summary
CLGN Quant Ranking